tesevatinib tesevatinib tesevatinib (kd019, xl647) is an experimental drug proposed for use in kidney cancer and polycystic kidney disease. the drug was first developed by exelixis, inc. and was later acquired by kadmon corporation. tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (egfr; erbb1), epidermal growth factor receptor 2 (her2; erbb2), vascular endothelial growth factor receptor (vegfr), and ephrin b4 (ephb4). tesevatinibclinical dataroutes ofadministrationoral administration (tablets)pharmacokinetic dataelimination half-life50–70 hoursidentifiers iupac name n-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-quinazolin-4-amine cas number781613-23-8 ypubchem cid10458325drugbankdb11973 ychemspider32699556 yuniif6xm2tn5a1keggd11772 ychemical and physical dataformulac24h25cl2fn4o2molar mass491.39 g·mol−13d model (jsmol)interactive image smiles cn1c2c(c2c1)coc3cc4c(cc3oc)c(ncn4)nc5ccc(c(c5f)cl)cl inchi inchi=1s/c24h25cl2fn4o2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15h,5-6,9-11h2,1-2h3,(h,28,29,30)/t13-,14-,15+ ykey:hvxkqkfehmghsl-qkdcvejesa-n y the drug activity was initially studied in non-small cell lung cancer. in a 2007 pre-clinical study with xenograft tumors of an erlotinib-resistant cell line tesevatinib substantially inhibited the growth of these tumors. in polycystic kidney disease, a histological study of the drug effects and toxicity in rats and mice was published in july 2017. as of march 2019 the drug was in phase ii clinical trials for the treatment of polycystic kidney disease in adults and children.